Home › Ocular Hypertension
Ocular Hypertension clinical trials recruiting in the U.S.
22 studies for Ocular Hypertension are recruiting participants at sites across the United States.
Cities with the most studies
By state
Recently updated studies
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07675824A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07661329Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07075718iDose TR Administration in an Office-Based Surgery Setting
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07816692Clarifying the Optimal Application of SLT Therapy Trial
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT04967989Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT04401982Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT07588152Direct vs Standard SLT for Glaucoma: A Noninferiority Trial
Recruiting
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT0740815424-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RecruitingPhase 4
Ages 18 and older · All sexes · Updated May 1, 2026 · NCT07325240DSLT for Reducing Medication in Glaucoma
RecruitingObservational study
All ages · All sexes · Updated Apr 20, 2026 · NCT07390890Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Mar 30, 2026 · NCT07495852Automated Applanation Tonometry - Updated
Recruiting
Ages 18 and older · All sexes · Updated Mar 6, 2026 · NCT07298356Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT07217678Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 27, 2026 · NCT07400926Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
RecruitingPhase 4
Ages 45 and older · All sexes · Updated Jan 21, 2026 · NCT06848946Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Recruiting
Ages 18 and older · All sexes · Updated Dec 29, 2025 · NCT06629649Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RecruitingPhase 3
Ages 22 and older · All sexes · Updated Oct 20, 2025 · NCT07218783Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RecruitingPhase 3
Ages 22 and older · All sexes · Updated Oct 20, 2025 · NCT07218796A More Engaging Visual Field Test to Increase Use and Reliability in Pediatrics
RecruitingHealthy volunteers welcome
Ages 5 to 8 · All sexes · Updated Sep 10, 2025 · NCT02157025A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 22, 2025 · NCT07076303Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
Recruiting
Ages 18 and older · All sexes · Updated May 6, 2023 · NCT05844384Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 10, 2022 · NCT05401357From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.